Alvotech Gets US FDA Approval For Additional Manufacturing Capacity For Simlandi Biosimilar; Shares Up Pre-Bell
MT newswire2026/10/05 09:5205:52 AM EDT, 10/05/2026 (MT Newswires) -- Alvotech (ALVO) has received US Food and Drug Administration approval for a supplement to the biologics license application for AVT02, marketed as Simlandi in the US, the company said Monday. The move allows drug substance for the product to be manufactured in a second production suite at the company's facility in Reykjavik, Iceland, and further confirms resolution of FDA inspection-related matters at the site. Simlandi is Alvotech's biosimilar to Humira. The company's shares were up 5.9% in premarket activity.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Crypto prices
More
